SCHEMBL740928

SCHEMBL740928

CCCSc1ccncc1C(N)=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.51
SIRT3 Q9NTG7 1/20 0.51
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
SLC22A12 Q96S37 4/20 0.39
CYP1A2 P05177 1/20 0.38
PTGS2 P35354 1/20 0.38
CDC7 O00311 1/20 0.38
HSD17B10 Q99714 4/20 0.37
ALDH1A1 P00352 3/20 0.37
HTT P42858 2/20 0.37
HPGD P15428 2/20 0.37
KDM4E B2RXH2 2/20 0.37
KDM6B O15054 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
MKNK1 Q9BUB5 2/20 0.36
MKNK2 Q9HBH9 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7502164 0.90 SIRT3 (0.47) TDP1SIRT3CA12CA1CA2
SCHEMBL1328542 0.87 SIRT3 (0.54) TDP1SIRT3CA12CA1CA2
SCHEMBL1327240 0.78 SIRT3 (0.59) TDP1SIRT3CA12CA1CA2
SCHEMBL6780943 0.77 PTGS2 (0.53) CYP1A2PTGS2HSD17B10ALDH1A1HPGD
SCHEMBL16702153 0.75 HASPIN (0.43) TDP1CA12CA1CA2CA9
SCHEMBL6833176 0.74 SIRT3 (0.54) TDP1SIRT3CA12CA1CA2
SCHEMBL19986496 0.73 HASPIN (0.38) TDP1SIRT3CA12CA1CA2
SCHEMBL9002466 0.73 SIRT3 (0.61) TDP1SIRT3CYP1A2CDC7ALDH1A1
SCHEMBL16611699 0.72 HSD17B10 (0.49) TDP1SIRT3CA12CA1CA2
SCHEMBL13667410 0.72 HSD11B1 (0.49) TDP1SIRT3CYP1A2HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138168-B1 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-20 US disclosed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 TDP1 1049/4885SIRT3 2917/4885CA12 4770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.